| human | Q5 |
| P496 | ORCID iD | 0000-0002-6260-6943 |
| P106 | occupation | researcher | Q1650915 |
| Q92703279 | Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury |
| Q57461650 | Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study |
| Q48177736 | DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. |
| Q90659981 | HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers |
| Q92553015 | High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer |
| Q57464567 | KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR |
| Q90751277 | Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer |
| Q90659989 | Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors |
Search more.